Targeting Leukemia Stem Cells to Expand Treatment-Free Remission in CML

This narrative review maps emerging leukemia stem cell surface markers, signalling pathways, and epigenetic regulators that may extend treatment-free remission beyond what tyrosine kinase inhibitors alone can deliver.

📅 Journal publication: Sep 18, 2026 · Last updated: Oct 12, 2026

chronic myeloid leukaemialeukaemia stem cellstyrosine kinase inhibitorstreatment-free remissionCD26IL-1RAPHedgehog pathwayWnt/beta-cateninBCL6EZH2CAR T-cellepigeneticsnarrative reviewoncology pharmacy Oncology Pharmacy

Background Information

Novel therapies for CML aim to overcome resistance and improve remission.

Improving management of chronic myeloid leukemia (CML) by investigating novel therapeutic targets could increase treatment-free remission (TFR) rates. New molecular and immunotherapeutic targets have been identified that focus on leukemia stem cells (LSCs) and their role in treatment resistance. Current tyrosine kinase inhibitors (TKIs) are effective but limited by resistance; exploring these new targets can lead to better outcomes and potential curative approaches. Emerging targets in LSCs for CML therapy could enhance TFR rates and possibly achieve curative outcomes.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Dai J, Zheng P, Liu J, Cheng L, Zheng X, Chen L, Jiang J, Zheng Z

Citation: Dai J, Zheng P, Liu J, et al. Recent Advances in Chronic Myeloid Leukaemia (CML): Emerging Molecular and Immunotherapeutic Targets. Frontiers in bioscience (Landmark edition). 2026;31(9):48912. doi:10.31083/FBL48912

Article Links: PubMed · Journal / DOI

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Thanks for the feedback!

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →